Wall Street analysts predict that Heat Biologics Inc (NASDAQ:HTBX) will report sales of $3.32 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Heat Biologics’ earnings, with the highest sales estimate coming in at $6.95 million and the lowest estimate coming in at $1.20 million. Heat Biologics reported sales of $470,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 606.4%. The business is scheduled to announce its next quarterly earnings results on Monday, November 12th.
According to Zacks, analysts expect that Heat Biologics will report full year sales of $6.28 million for the current year, with estimates ranging from $4.30 million to $8.40 million. For the next fiscal year, analysts expect that the firm will post sales of $3.23 million, with estimates ranging from $2.40 million to $4.80 million. Zacks’ sales averages are an average based on a survey of research firms that that provide coverage for Heat Biologics.
Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.09). The company had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.11 million. Heat Biologics had a negative return on equity of 116.28% and a negative net margin of 437.62%.
A number of equities analysts have recently commented on the stock. Eurobank EFG started coverage on shares of Heat Biologics in a report on Monday, July 9th. They issued a “buy” rating and a $11.00 price target on the stock. HC Wainwright started coverage on shares of Heat Biologics in a report on Tuesday, June 26th. They set a “buy” rating and a $6.00 target price on the stock. Finally, Brookline Cap M reaffirmed a “buy” rating on shares of Heat Biologics in a report on Wednesday, August 1st.
A hedge fund recently bought a new stake in Heat Biologics stock. Northern Trust Corp bought a new stake in shares of Heat Biologics Inc (NASDAQ:HTBX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 51,512 shares of the biopharmaceutical company’s stock, valued at approximately $111,000. Northern Trust Corp owned about 0.22% of Heat Biologics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.41% of the company’s stock.
Shares of NASDAQ:HTBX traded up $0.05 during trading on Wednesday, reaching $1.72. The company had a trading volume of 194,525 shares, compared to its average volume of 898,739. Heat Biologics has a 12 month low of $1.09 and a 12 month high of $7.00.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Featured Article: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.